Literature DB >> 18803278

Delayed-onset HIT caused by low-molecular-weight heparin manifesting during fondaparinux prophylaxis.

Khalid A Alsaleh1, Sami M A Al-Nasser, Shannon M Bates, Ameen Patel, Theodore E Warkentin, Donald M Arnold.   

Abstract

Heparin-induced thrombocytopenia (HIT) is a prothrombotic condition caused by platelet-activating antibodies that react with platelet factor 4 (PF4)/heparin complexes. Delayed-onset HIT occurs after heparin is stopped. Fondaparinux, a synthetic pentasaccharide, is thought to be a safe alternative anticoagulant in HIT. We describe a patient with delayed-onset HIT triggered by low-molecular-weight heparin (LMWH) which occurred during fondaparinux prophylaxis and which was complicated by microangiopathic hemolytic anemia. Patient serum contained high-titer anti-PF4/heparin antibodies demonstrating heparin-dependent platelet activation with serial dilutions. Confirmed delayed-onset HIT with LMWH has not been previously reported. Low dose fondaparinux does not necessarily prevent thrombotic complications of HIT. Copyright 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18803278     DOI: 10.1002/ajh.21273

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  11 in total

Review 1.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Lori-Ann Linkins; Antonio L Dans; Lisa K Moores; Robert Bona; Bruce L Davidson; Sam Schulman; Mark Crowther
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  A case of unsuccessful treatment of heparin-induced thrombocytopenia (HIT) with fondaparinux.

Authors:  Aimon C Miranda; Jennifer L Donovan; Maichi T Tran; Joel M Gore
Journal:  J Thromb Thrombolysis       Date:  2012-01       Impact factor: 2.300

3.  Successful use of fondaparinux in a patient with a mechanical heart valve replacement and a history of heparin-induced thrombocytopenia.

Authors:  Tia L Corbett; Kathy S Elher; Candice L Garwood
Journal:  J Thromb Thrombolysis       Date:  2010-10       Impact factor: 2.300

4.  Heparin enhances uptake of platelet factor 4/heparin complexes by monocytes and macrophages.

Authors:  M Joglekar; S Khandelwal; D B Cines; M Poncz; L Rauova; G M Arepally
Journal:  J Thromb Haemost       Date:  2015-07-14       Impact factor: 5.824

Review 5.  Structural Features and PF4 Functions that Occur in Heparin-Induced Thrombocytopenia (HIT) Complicated by COVID-19.

Authors:  Zheng Cai; Mark I Greene; Zhiqiang Zhu; Hongtao Zhang
Journal:  Antibodies (Basel)       Date:  2020-10-10

6.  BILATERAL ADRENAL HEMORRHAGE WITH ADRENAL INSUFFICIENCY AFTER DALTEPARIN USE POST HIP ATHROPLASTIES.

Authors:  Robyn L Houlden; Azraa Janmohamed
Journal:  AACE Clin Case Rep       Date:  2020-05-08

7.  Role of factor xa inhibitors in cancer-associated thrombosis: any new data?

Authors:  Ali Zalpour; Michael H Kroll; Vahid Afshar-Kharghan; Syed Wamique Yusuf; Carmen Escalante
Journal:  Adv Hematol       Date:  2011-10-15

8.  A rare case of fondaparinux-induced major bleeding in postmenopausal woman prescribed for non-ST segment elevation Ml.

Authors:  Vishal R Tandon; Sudhaa Sharma; Shagun Mahajan; Annil Mahajan; Vijay Khajuria
Journal:  J Midlife Health       Date:  2013-10

Review 9.  Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism.

Authors:  Maureen A Smythe; Jennifer Priziola; Paul P Dobesh; Diane Wirth; Adam Cuker; Ann K Wittkowsky
Journal:  J Thromb Thrombolysis       Date:  2016-01       Impact factor: 2.300

Review 10.  Functional Assays in the Diagnosis of Heparin-Induced Thrombocytopenia: A Review.

Authors:  Valentine Minet; Jean-Michel Dogné; François Mullier
Journal:  Molecules       Date:  2017-04-11       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.